<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
DATE OF REPORT - JUNE 12, 2000
(Date of earliest event reported)
ALKERMES, INC.
(Exact name of Registrant as specified in its charter)
PENNSYLVANIA 0-19267 23-2472830
(State of incorporation) (Commission file number) (IRS employer
identification
number)
64 SIDNEY STREET, CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices, zip code)
AREA CODE (617) 494-0171
(Telephone number)
<PAGE> 2
ITEM 5. OTHER INFORMATION.
As reported in the press release of Alkermes, Inc. (the "Company")
published June 12, 2000, the Company announced that R.W. Johnson Pharmaceutical
Research Institute, a Johnson & Johnson Company, had terminated further
development of an injectable sustained release formulation of erythropoietin
based on Alkermes' ProLease(R) drug delivery technology. The entire text of the
Company's press release is incorporated by reference herein and a copy has been
filed as an exhibit to this report.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
99 Press Release, dated June 12, 2000
2
<PAGE> 3
SIGNATURES
Pursuant to requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Dated: June 23, 2000 Alkermes, Inc.
By: /s/ James M. Frates
-------------------------------
James M. Frates
Vice President, Chief Financial
Officer and Treasurer
3
<PAGE> 4
ALKERMES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
EXHIBIT NO. EXHIBIT
99 Press Release, dated June 12, 2000
4
